Abstract: Disclosed herein are compounds useful for modulating the mu-opioid receptor (“MOR”) and/or delta-opioid receptor (“DOR”), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.

Abstract: Disclosed herein are compounds useful for modulating the mu-opioid receptor (“MOR”) and/or delta-opioid receptor (“DOR”), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.

Abstract: The invention relates to synthetic peptide analogs of D-Arg-Oic-Pro-Gly-Phe and methods of their use to inhibit human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4.

Abstract: Novel compounds which are capable of binding with enhanced specificity to the delta receptor are disclosed. The compounds are a series of cyclic, conformationally constrained analogs of enkephalins which display exceptional delta receptor specificity. The compounds of the present invention are polypeptides of the formula: ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, methyl, or lower alkyl having 1 to 5 carbon atoms;R.sup.3 and R.sup.4, which may be the same or different, are hydrogen, methyl, or lower alkyl having 1 to 5 carbon atoms, provided, however that R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may not all be hydrogen when both n and m are zero;R.sup.5 is hydrogen, L-tyrosine, D-tyrosine, or L-tyrosine or D-tyrosine substituted on the N.sup..alpha. -amino with 1 or 2 lower alkyl or alkenyl groups;R.sup.6 is a substituted or unsubstituted aromatic;R.sup.7 is hydrogen or methyl;R.sup.